Company news
Karyopharm Therapeutics Inc. news in 2022
Karyopharm Therapeutics Inc.'s news releases, calls and decks from 2022, newest first.
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022
December 11, 2022
Karyopharm Announces $165 Million Private Placement
December 4, 2022
Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 2, 2022
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
October 31, 2022
Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
August 3, 2022
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
July 20, 2022
Karyopharm Granted Regulatory Designations for Eltanexor for the Treatment of Myelodysplastic Syndromes
July 19, 2022
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
May 19, 2022
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress
May 11, 2022
Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022
April 27, 2022
Karyopharm Announces Selinexor Data to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting
April 26, 2022
Karyopharm Announces Further Transition of Co-Founders Sharon Shacham PhD, MBA and Michael Kauffman, MD, PhD and appointment of Reshma Rangwala, MD, PhD as Chief Medical Officer
March 28, 2022
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer
March 15, 2022
Karyopharm Names New Head of Investor Relations
March 13, 2022
Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer
February 28, 2022
Karyopharm Announces Changes to Its Clinical Leadership Team
February 21, 2022
Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
February 7, 2022
Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer
February 7, 2022
Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes
January 23, 2022
Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer
January 9, 2022
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives
January 9, 2022
Calls in 2022
- Karyopharm Therapeutics (NASDAQ:KPTI) Q3 2022 Earnings Call
Nov 3, 2022
Transcript - Karyopharm Therapeutics (NASDAQ:KPTI) Q2 2022 Earnings Call
Aug 4, 2022
Transcript - Karyopharm Therapeutics (NASDAQ:KPTI) Q1 2022 Earnings Call
May 5, 2022
Transcript - Karyopharm Therapeutics (NASDAQ:KPTI) Q4 2021 Earnings Call
Jan 11, 2022
Transcript
Decks in 2022
- SGO Annual Meeting on Women's Cancer 2022
Conference · 28 slides · March 2022
- Technical Presentation (March 2022)
Technical · 25 slides · March 2022